Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
DATA GRAPHICS | Product Development

OX40L pipeline: Data Byte

By Danielle Golovin, Staff Writer
January 12, 2021 3:21 AM UTC

Kymab leads the pack among companies targeting OX40L for autoimmune disorders, while Moderna has the most advanced program against the target for cancer. 

OX40L, the ligand for the OX40 receptor, is expressed on activated antigen-presenting cells, while the OX40 receptor is expressed on activated T cells. The interaction between OX40 and OX40L provides a co-stimulatory signal that regulates the proliferation and survival of T cells. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Abbvie Inc.

Dnatrix Inc.

Hifibio Inc.

Ichnos Sciences Inc.

Kymab Group Ltd.

Kymab Group Ltd.

Moderna Inc.